Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease Study Group

Highlight of trial implications for diabetes management and recent perspectives of diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners. (Cardiovascular Diabetology 2018 Feb 19)

1 March Mar 2018 2 months ago
  • Genovese S

The 3rd Cardiovascular Outcome Trial Summit of the Diabetes & Cardiovascular Disease EASD Study Group was held on the 26-27 October 2017 in Munich. As in 2015 and 2016, this summit was organised in light of recently completed and published CVOTs on diabetes, aiming to serve as a reference meeting for in-depth discussions on the topic. Amongst others, the CVOTs EXSCEL, DEVOTE, the CANVAS program and the ACE-trial, which released primary outcome results in 2017, were discussed.

Trial implications for diabetes management and recent perspectives of diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners were highlighted. The clinical relevance of cardiovascular outcome trials and its implications regarding reimbursement were compared with real-world studies.

Reference

  • Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Lalic K, Skrha J, Valensi P, Ceriello A. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol 2018 Feb 19;17(1):30 Go to PubMed